Left Prefrontal Repetitive Transcranial Magnetic Stimulation in Schizophrenia

Holi, Matti; Eronen, Markku; Toivonen, Kari; Toivonen, Päivi; Marttunen, Mauri; Naukkarinen, Hannu

doi:10.1093/oxfordjournals.schbul.a007089

Cited by 83 publications

(56 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was underlined by a study which reported a significant improvement in negative symptoms in 20 schizophrenic patients treated with 10 Hz high-frequency rTMS compared to sham stimulation (Hajak et al 2004). In contrast to these encouraging results, a recently published study showed no significant effect of 10 Hz rTMS over left dorsolateral prefrontal cortex in 22 chronically hospitalised schizophrenic patients compared to sham (Holi 2004). The severity of disease and dosage of medication were discussed as possible explanations for the missing effect.…”

Section: Repetitive Transcranial Magnetic Stimulation (Rtms)mentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

Falkai

Wobrock

Lieberman

et al. 2006

The World Journal of Biological Psychiatry

201

View full text Add to dashboard Cite

These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A Á/D). This second part of the guidelines covers the long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.Key words: Schizophrenia, long-term treatment, evidence-based medicine, practice guidelines, biological treatment, antipsychotics EXECUTIVE SUMMARY OF RECOMMENDATIONS General recommendationsSpecific treatment strategies are required not only for patients suffering from acute schizophrenia, but also in the stabilisation and stable phase of the disease. The stabilisation period follows the acute phase and constitutes a time-limited transition to continuing treatment in the stable phase. The stable phase represents a prolonged period of treatment and rehabilitation during which symptoms are under adequate control and the focus is on improving functioning and recovery. The goals of long-term therapy have to be discussed with the patient on the background of adequately provided information and his personal goals in order to find common ground to encourage a long-term medication strategy (shared-decision making). In this regard a treatment plan must be formulated and implemented. During the stabilisation phase, the main goals of treatment are to facilitate continued reduction in symptoms, consolidate remission, and promote the process of recovery. The main goals of treatment during the stable phase are to ensure that symptom remission or control is sustained, that the patient is maintaining or improving the level of functioning and quality of life, to prevent relapse, and to ensure that monitoring for adverse treatment effects continues. The antipsychotic pharmacological therapy should be accompanied by psychosocial interventions. A number of psychosocial...

show abstract

Section: Repetitive Transcranial Magnetic Stimulation (Rtms)mentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

Falkai

Wobrock

Lieberman

et al. 2006

The World Journal of Biological Psychiatry

201

View full text Add to dashboard Cite

show abstract

“…Cordes et al [20], found mild to moderate effect using 10 Hz stimulation at 110 % MT in a sham-controlled trial of 35 individuals with chronic schizophrenia. In a group of 22 chronic, hospitalized patients with schizophrenia, high-frequency TMS was not found to have a therapeutic effect [21]. Novak et al [22], were unable to show that high-frequency rTMS over the left DLPFC would decrease negative symptoms in 16 patients with schizophrenia.…”

Section: Effect Of Rtms On Negative Symptomsmentioning

confidence: 97%

Use of Repetitive Transcranial Magnetic Stimulation in Treatment of Negative Symptoms of Schizophrenia

Sayar¹,

Bulut²,

Tarhan³

2015

J Neurol Neurol Sci Disord

View full text Add to dashboard Cite

“…Therefore, in neuropsychiatric disorders where particular brain regions or networks exhibit diminished activity, anodal stimulation would be used to increase activity in these hypofunctioning regions. Conversely, cathodal stimulation could modulate hyperactive regions [65][66][67][68].…”

Section: Transcranial Direct Current Stimulationmentioning

confidence: 99%

Novel Treatments of Psychosis

Dunn

Marder

2015

Curr Behav Neurosci Rep

View full text Add to dashboard Cite

Since the advent of chlorpromazine in the 1950s, D 2 receptor antagonist activity has been synonymous with antipsychotic medications. This single mechanism of action may explain the similarities in efficacy among approved antipsychotics. Additionally, extrapyramidal and metabolic side effects of antipsychotics present a significant burden to patient quality of life. Development of the next generation of antipsychotics has focused on novel mechanisms of action including drugs that act through the N-methyl-D-aspartate (NMDA) system, modify second messenger activity, and modulate neuronal firing. This review surveys a selection of novel treatments with activity against positive symptoms. Each section includes a brief description of their mechanism of action, summarizes studies evaluating their clinical efficacy, and comments on safety and tolerability issues. Included in this review are compounds originally developed for treating psychotic disorders such as pimavanserin, pomaglumetad, and bitopertin. Other interventions are off-label uses of existing treatments such as bexarotene, rTMS, and sodium nitroprusside.

show abstract

Left Prefrontal Repetitive Transcranial Magnetic Stimulation in Schizophrenia

Cited by 83 publications

References 20 publications

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

Use of Repetitive Transcranial Magnetic Stimulation in Treatment of Negative Symptoms of Schizophrenia

Novel Treatments of Psychosis

Contact Info

Product

Resources

About